Clinical trials: Hip Pain
Chronic Osteoarthritis
OXN PR Compared to OxyPR to Demonstrate Non-inferiority in Pain & Locomotor Function & Improvement in Symptoms of Constipation in OA Subjects
The primary objectives are to demonstrate that the treatment with OXN PR tablets is non-inferior to the treatment with OxyPR with regards to analgesic efficacy and locomotor function.
- Trial name
- NCT00902837
- Testing
- Oxycodone naloxone prolonged release tablets (OXN), oxycodone prolonged release tablet, oxycodone naloxone tablet
- Where
- 36 sites in Belgium, Czechia and 4 more
- Volunteers
- 181 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Osteoarthritis of the Knee or Hip
Long-Term Safety and Efficacy Study of Fasinumab in Patients With Pain Due to Osteoarthritis (OA) of the Knee or Hip
The primary objective of the study is to describe the safety and tolerability of fasinumab, including adverse events of special interest (AESIs), in patients with pain due to radiographically-confirmed OA of the knee or hip.
- Trial name
- FACT LTS & OA (NCT02683239)
- Testing
- Fasinumab
- Where
- 149 sites in United States, Bulgaria and 19 more
- Volunteers
- 5,331 people
- Sponsor
- Regeneron Pharmaceuticals
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROFEMUR® Gladiator HA Coated Modular Femoral Stems
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) and resurfacing components marketed in the European Union (EU).
- Trial name
- NCT02314611
- Testing
- PROFEMUR® Gladiator HA Coated Modular Femoral Stem
- Where
- Belgium
- Volunteers
- 154 people
- Sponsor
- MicroPort Orthopedics Inc.
Osteoarthritis, Pain
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of fulranumab as Monotherapy compared with placebo in participants with signs and symptoms of osteoarthritis of the hip or knee that are not…
- Trial name
- NCT02336698
- Testing
- Fulranumab 1 mg, Fulranumab 3 mg
- Where
- 32 sites in United States, Poland and 2 more
- Volunteers
- 18 people
- Sponsor
- Janssen Research & Development, LLC
Pain
Study to Evaluate The Analgesic Efficacy and Safety of Intravenous Paracetamol in Subjects With Postoperative Pain After Total Hip Arthroplasty
The main purpose is to evaluate the analgesic efficacy of 1g of intravenous (Iv) paracetamol versus i.v. placebo, administered every 6h, as measured by the reduction of the 24-hour cumulative dose of the opioid tramadol in the…
- Trial name
- NCT00344045
- Testing
- Paracetamol
- Where
- 5 sites in Spain
- Volunteers
- 86 people
- Sponsor
- Bristol-Myers Squibb
Idiopathic Hip Pain, Chronic Hip Pain
Clinical Trial for Idiopathic Hip Pain Using Peripheral Nerve Stimulation
This is a prospective, randomized, multi-center study in which 300 evaluable subjects will be randomized 1:1 to receive Active or Delayed therapy with Moventis PNS.
- Trial name
- NCT05074329
- Testing
- Moventis PNS
- Volunteers
- 300 people
- Sponsor
- Uro Medical Corporation
Osteoarthritis, Knee, Osteoarthritis, Hip
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
The primary objective of the study is to evaluate the effect of fasinumab compared to placebo on peripheral nerves in participants with pain due to Osteoarthritis (OA) of the hip or knee.
- Trial name
- NCT03691974
- Testing
- Fasinumab
- Where
- 47 sites in United States, Poland and 1 more
- Volunteers
- 180 people
- Sponsor
- Regeneron Pharmaceuticals
Osteoarthritis
Safety and Efficacy of Buprenorphine Transdermal System in Subjects With Moderate to Severe Osteoarthritis of Hip or Knee
The objective of this study is to demonstrate the effectiveness and tolerability of the buprenorphine transdermal system (BTDS) (5, 10 and 20) in comparison to placebo transdermal system in subjects with moderate to severe…
- Trial name
- NCT00313846
- Testing
- Buprenorphine transdermal patch
- Where
- 44 sites in United States
- Volunteers
- 529 people
- Sponsor
- Purdue Pharma LP
Osteoarthritis
Study of Diclofenac Capsules to Treat Osteoarthritis Pain
The purpose of this study is to determine whether Diclofenac [Test] Capsules are safe and effective for the treatment of osteoarthritis pain of the hip or knee.
- Trial name
- NCT01461369
- Testing
- Diclofenac
- Where
- 40 sites in United States
- Volunteers
- 305 people
- Sponsor
- Iroko Pharmaceuticals, LLC
Joint Disease
Post Market Clinical Follow-Up Study Protocol for PROCOTYL® C Acetabular Components
MicroPort Orthopedics (MPO) is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU).
- Trial name
- NCT03576573
- Testing
- PROCOTYL® C
- Where
- Germany
- Volunteers
- 143 people
- Sponsor
- MicroPort Orthopedics Inc.
Osteoarthritis
Safety of BTDS in Subjects With Osteoarthritic (OA) Pain of Hip or Knee: A 6-Month Open-label Extension Phase
The purpose of the extension phase is to evaluate the long-term safety and tolerability of buprenorphine transdermal system (BTDS).
- Trial name
- NCT01141283
- Testing
- Buprenorphine transdermal patch
- Where
- 42 sites in United States
- Volunteers
- 290 people
- Sponsor
- Purdue Pharma LP
Chronic Pain
A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic Osteoarthritis (OA) Pain
To evaluate the efficacy of OROS Hydromorphone in reducing moderate to severe chronic pain in patients with Osteoarthritis (OA) Pain
- Trial name
- NCT00631319
- Testing
- OROS hydromorphone
- Volunteers
- 343 people
- Sponsor
- Mallinckrodt